Friday, December 09, 2022 9:52:48 AM
Due Dilligence is Vital. Give me a Member Mark if you want to consistently track winners with strong due dilligence behind it
Recent SMMT News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:03:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2024 11:48:42 AM
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 • Business Wire • 05/01/2024 11:00:00 AM
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 • Business Wire • 04/24/2024 08:30:00 PM
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors • Business Wire • 04/11/2024 08:30:00 PM
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum • Business Wire • 04/10/2024 11:00:00 AM
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 • Business Wire • 03/22/2024 11:00:00 AM
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 • Business Wire • 03/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:05:09 PM
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:05:51 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 12:55:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 12:32:56 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 02/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:25:38 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:35:18 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 • Business Wire • 02/14/2024 03:29:00 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 • Business Wire • 02/14/2024 12:00:00 PM
- Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:07:05 PM
- Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:33:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:22:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:06:38 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM